Discovery of Novel Substrate-Competitive Lysine Methyltransferase G9a Inhibitors as Anticancer Agents
作者:Yosuke Nishigaya、Shohei Takase、Tatsunobu Sumiya、Ko Kikuzato、Tomohiro Sato、Hideaki Niwa、Shin Sato、Akiko Nakata、Takeshi Sonoda、Noriaki Hashimoto、Ryosuke Namie、Teruki Honma、Takashi Umehara、Mikako Shirouzu、Hiroo Koyama、Minoru Yoshida、Akihiro Ito、Fumiyuki Shirai
DOI:10.1021/acs.jmedchem.2c02059
日期:2023.3.23
Identification of structurally novel inhibitors of lysine methyltransferase G9a has been a subject of intense research in cancer epigenetics. Starting with the high-throughput screening (HTS) hit rac-10a obtained from the chemical library of the University of Tokyo Drug Discovery Initiative, the structure–activity relationship of the unique substrate-competitive inhibitors was established with the
结构新颖的赖氨酸甲基转移酶 G9a 抑制剂的鉴定一直是癌症表观遗传学研究的重点。以东京大学药物发现计划化学图书馆获得的高通量筛选(HTS)命中的rac - 10a为起点,借助X射线晶体学建立了独特底物竞争性抑制剂的构效关系和片段分子轨道(FMO)计算配体-蛋白质相互作用。体外特性以及药物代谢和药代动力学 (DMPK) 特性的进一步优化导致了26j (RK-701) 的鉴定,它是一种结构独特的 G9a/GLP 强效抑制剂 (IC 50 = 27/53 nM)。化合物26j对其他相关甲基转移酶表现出显着的选择性,对细胞 H3K9me2 水平具有剂量依赖性减弱作用,并且在体外对 MOLT-4 细胞中的肿瘤生长具有抑制作用。此外,化合物26j在致癌物诱导的肝细胞癌 (HCC)体内小鼠模型中显示出对肿瘤发生和生长的抑制作用,且没有明显的急性毒性。